Your session is about to expire
← Back to Search
Retinoid
Delgocitinib Cream and Alitretinoin for Chronic Hand Dermatitis
Phase 3
Waitlist Available
Research Sponsored by LEO Pharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Diagnosis of CHE, defined as hand eczema that has persisted for more than 3 months or returned twice or more within the last 12 months
Disease severity graded as moderate to severe at screening and baseline according to IGA-CHE (i.e. an IGA-CHE score of 3 or 4)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 26 weeks
Awards & highlights
Study Summary
This trial will last 24 weeks and will compare the efficacy of delgocitinib cream and alitretinoin capsules in participants with severe chronic hand eczema.
Eligible Conditions
- Chronic Hand Dermatitis
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
You have had hand eczema for more than 3 months, or it has come back two or more times in the last year.
Select...
Your skin condition is classified as moderate to severe based on a specific scoring system.
Select...
You have tried using topical corticosteroids and they did not work well for you, or they are not safe for you to use due to side effects or other risks.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 26 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~26 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in HECSI score from baseline to Week 12
Secondary outcome measures
AUC of HECSI-90 from baseline up to Week 24
AUC of change from baseline in DLQI score up to Week 24
Change in HECSI score from baseline to Week 24
+7 moreTrial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Delgocitinib cream 20 mg/gExperimental Treatment1 Intervention
Twice-daily topical application for up to 24 weeks
Group II: Alitretinoin capsules 30 mg per capsuleActive Control1 Intervention
1 capsule per day for up to 24 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Delgocitinib
2021
Completed Phase 3
~1330
Find a Location
Who is running the clinical trial?
LEO PharmaLead Sponsor
268 Previous Clinical Trials
187,938 Total Patients Enrolled
Medical ExpertStudy DirectorLEO Pharma
53 Previous Clinical Trials
9,588 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I'm sorry, but I would need more context or information to accurately summarize this criterion in plain language. Can you please provide more details or clarify your request?You follow regular skin care without using any special medications and avoid things that may irritate or cause an allergic reaction to your skin.You currently have a skin condition on your hands, like a fungal infection called tinea manuum.You have a serious infection on your hands.You currently have psoriasis anywhere on your body.You have used antibiotics by mouth or on your skin in the past two weeks.You have used tanning beds, phototherapy, or bleach baths on your hands in the last 28 days before the study starts.You are not able to take alitretinoin.You have a positive test for hepatitis B or hepatitis C.You have a known immune system disorder or have tested positive for HIV, or are taking medications for HIV.You have been diagnosed with chronic hand eczema that has lasted for more than 3 months or has come back two or more times in the last year.You have taken Janus kinase (JAK) inhibitors, like delgocitinib/LEO 124249, in the past.You have rough, scaly skin on your hands along with a history of psoriasis anywhere on your body.Your skin condition is graded as moderate to severe according to a specific scale called IGA-CHE.You have a skin condition that needs ongoing treatment, except on your hands and feet.You have received certain biological treatments in the past few months that may affect your immune system.You have used alitretinoin before or been in a study involving alitretinoin or delgocitinib.You have had hand eczema for more than 3 months, or it has come back two or more times in the last year.Your skin condition is classified as moderate to severe based on a specific scoring system.You have recently tried using topical corticosteroids and they did not work well for you, or it's not safe for you to use them because of side effects or other risks.You have used certain skin treatments on your hands within 14 days before the start of the study.You have taken certain medications that affect the immune system within the last 28 days.You have tried using topical corticosteroids and they did not work well for you, or they are not safe for you to use due to side effects or other risks.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there risks associated with taking Delgocitinib?
"There is some evidence to support the efficacy of Delgocitinib and it has been through multiple rounds of testing, so we have rated its safety as a 3."
Answered by AI
How many locations are participating in this research project?
"There are 11 sites conducting this clinical trial at the moment. They are located in cities such as Calgary, Guelph and Vancouver. If you decide to participate in this study, try to select the clinic closest to your home to reduce travel time commitments."
Answered by AI
How many individuals are being asked to participate in this clinical trial?
"Yes, this trial is still looking for participants according to the information available on clinicaltrials.gov. This page was created on 6/15/2022 and updated as recently as 11/4/2022. If you are eligible and interested, please note that there are a total of 510 patients needed at 11 different locations."
Answered by AI
Are there any empty seats in this clinical trial?
"According to the information available on clinicaltrials.gov, this trial is still looking for participants and is accepting applications. The original posting date was June 15th, 2022 and the page has been updated as recently as November 4th, 2022."
Answered by AI
Who else is applying?
How old are they?
18 - 65
What site did they apply to?
LEO Pharma investigational site
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger